ABL

Advanced Biological Laboratories (ABL) was established in 2000 as a spin-off from CRP-Santé Luxembourg, emerging from the intersection of molecular biology expertise and information technology. The company was founded with a clear vision: to address critical gaps in infectious disease diagnostics by developing comprehensive solutions that bridge cutting-edge laboratory testing with sophisticated software analysis.

Over more than two decades, ABL has evolved into a European biotechnology and MedTech group that specializes in innovative molecular biology assays and diagnostic software. The company's portfolio includes proprietary solutions for detecting and genotyping infectious pathogens such as HIV, Hepatitis B and C, Human Papillomavirus, Cytomegalovirus, Tuberculosis, and SARS-CoV-2. ABL's DeepChek® and UltraGene™ product lines represent the core of their offerings, enabling clinical laboratories to perform viral load quantification and drug resistance genotyping through advanced sequencing technologies including Next Generation Sequencing and Sanger sequencing.

In addition to their diagnostic assays, ABL has developed integrated software platforms like ViroScore® and DeepChek® software that provide comprehensive data analysis and management capabilities for clinical laboratories. The company operates multiple subsidiaries including CDL Pharma, which focuses on biological sample management and clinical trial logistics, and Humedics, a Berlin-based MedTech company specializing in liver function measurement technologies.